FREMONT, Calif., April 18, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) diseases, today announced that it will present clinical and preclinical data during two poster presentations at the following upcoming medical meetings:
National Kidney Foundation Spring Clinical Meetings, April 18 - 22, 2017, in Orlando, Fla.
Date and Time: Wednesday, April 19, 2017 from 6:00 - 7:30p.m. ET
Poster Title: Effect of Tenapanor on Serum Fibroblast Growth Factor 23 Levels
Poster Number: 193
Digestive Disease Week, May 6 - 9, 2017, in Chicago
Date and Time: Tuesday, May 9, 2017 from 12:00 - 2:00p.m. CT
Session Title: Clinical Steatohepatitis
Poster Title: Minimally-systemic TGR5 agonist RDX8940 improves hepatic steatosis and insulin sensitivity in Western-diet-fed mice
Poster Number: Tu1559
About Ardelyx, Inc.
Ardelyx is focused on enhancing the way patients with cardiorenal and gastrointestinal (GI) diseases are treated by using the gut as the gateway to delivering medicines that matter. The company has established unique cardiorenal and GI business units aimed at bringing new, effective medicines with distinct safety and dosing advantages to underserved patients. Ardelyx's cardiorenal portfolio includes the Phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and the Phase 3 development of RDX7675 for the treatment of people with hyperkalemia. The company's GI portfolio includes the Phase 3 development of tenapanor for
the treatment of people with irritable bowel syndrome with constipation (IBS-C), and RDX8940, a TGR5 agonist approaching Phase 1 development. Leveraging the company's platform and unique gut-restriction chemistry, Ardelyx intends to build a fully integrated, revenue-generating biopharmaceutical company with leading cardiorenal and GI business units. For more information, please visit www.ardelyx.com and connect with us on Twitter @Ardelyx.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including the potential for Ardelyx's product candidates in treating the diseases and conditions for which they are being developed and Ardelyx's corporate plans and goals. Such forward-looking statements involve substantial risks and uncertainties that could cause the development of Ardelyx's product candidates or Ardelyx's future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in research and the clinical development. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx's business in general, please refer to Ardelyx's Quarterly Report on Form 10-K filed with the Securities and Exchange Commission on
February 17, 2017, and its future current and periodic reports to be filed with the Securities and Exchange Commission.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-upcoming-spring-medical-meetings-300440554.html